The WJTOG3405 trial reported that the median OS of advanced NSCLC patients with mutated EGFR treated with first-generation EGFR-TKIs was up to 30.2 months, which is much longer than that of patients treated with chemotherapy (102). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.